Scilex Holding Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Scilex Holding şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-65.9%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-65.9%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Analysts Just Shaved Their Scilex Holding Company (NASDAQ:SCLX) Forecasts Dramatically

Jun 14

It's Down 33% But Scilex Holding Company (NASDAQ:SCLX) Could Be Riskier Than It Looks

Apr 24

Scilex Holding Company's (NASDAQ:SCLX) 35% Price Boost Is Out Of Tune With Revenues

Feb 28

Risks To Shareholder Returns Are Elevated At These Prices For Scilex Holding Company (NASDAQ:SCLX)

Dec 21

Scilex Holding Company's (NASDAQ:SCLX) 56% Dip In Price Shows Sentiment Is Matching Earnings

May 06

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: SCLX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: SCLX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Scilex Holding Piyasaya Karşı Temettü Getirisi

SCLX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (SCLX)	n/a
Pazarın Alt %25'i (US)	1.3%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Pharmaceuticals)	2.4%
Analist tahmini (SCLX) (3 yıla kadar)	n/a

Önemli Temettü: SCLX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, SCLX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: SCLX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: SCLX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Scilex Holding Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Scilex Holding Announces Receipt of Notice from Nasdaq

Scilex Holding Company announced delayed 10-Q filing

New minor risk - Shareholder dilution

Scilex Holding Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Consensus EPS estimates upgraded to US$0.74 loss, revenue downgraded

Price target increased by 43% to US$7.63

Scilex Holding Company has completed a Follow-on Equity Offering in the amount of $50 million.

Scilex Holding Company Provides Preliminary Unaudited Sales Guidance for the Quarter Ended September 30, 2024

Scilex Holding Company has filed a Follow-on Equity Offering.

Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA Label

Consensus EPS estimates fall by 62%, revenue upgraded

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Scilex Holding Company Provides Preliminary Unaudited Sales Guidance for the Month Ended July 31, 2024

Scilex Holding Company Appoints Annu Navani as Board of Directors

Scilex Holding Company Announces Publication in Pain Journal Regarding Phase 3 Results of the Pivotal Registration Trial of Sp-102 (Semdexa™) in Lumbosacral Radicular Pain (Sciatica)

Analysts Just Shaved Their Scilex Holding Company (NASDAQ:SCLX) Forecasts Dramatically

Consensus revenue estimates fall by 19%

Scilex Holding Company Announces FDA Approval of Commercial Manufacturing of Gloperba

President recently bought US$122k worth of stock

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Scilex Holding Company has completed a Follow-on Equity Offering in the amount of $15 million.

It's Down 33% But Scilex Holding Company (NASDAQ:SCLX) Could Be Riskier Than It Looks

Scilex Holding Company has filed a Follow-on Equity Offering.

New minor risk - Market cap size

Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba®? Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment Is Needed

Scilex Holding Company and Scilex Pharmaceuticals, Inc. Announces Settlement Agreement with Takeda Pharmaceuticals Company Ltd and Takeda Pharmaceuticals U.S.A., Inc

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Scilex Holding Company, Annual General Meeting, Apr 05, 2024

Scilex Holding Company has filed a Follow-on Equity Offering.

Scilex Holding Company's (NASDAQ:SCLX) 35% Price Boost Is Out Of Tune With Revenues

Scilex Holding Company Provides Sales Guidance for the Fiscal Year Ended December 31, 2023

Scilex Holding Company Announces Filing of New Drug Submission to Health Canada's Pharmaceutical Drugs Director, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada

Scilex Holding Company has filed a Follow-on Equity Offering in the amount of $170 million.

Scilex Holding Company has filed a Follow-on Equity Offering in the amount of $170 million.

Risks To Shareholder Returns Are Elevated At These Prices For Scilex Holding Company (NASDAQ:SCLX)

High number of new and inexperienced directors

Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal A High Degree of Interest in Gloperba as Liquid Colchicine Formulation Designed for Precision Dosing

Scilex Holding Company Announces ZTlido Will Be Added as a Preferred Agent to the Medicaid Preferred Drug List (PDL) in Two New States: One Midwestern and One Southern State

Scilex Holding Company Announces the Addition of Ztlido (Lidocaine Topical System) as A Preferred Agent to the Medicaid Preferred Drug List (Pdl) of the State of the State of Tennessee

Scilex Holding Company Announces Successful Fda Audit of Enhanced Ztlido®? Manufacturing Facility in Japan

Scilex Holding Company Announces Completion of Commercial Manufacturing of Gloperba

Scilex Holding Company Announces Completion of Commercial Manufacturing of Gloperba

Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs in Treating Acute Migraine Targeted by ELYXYB

Scilex Holding Company Announces Production Increase, Product Availability

Scilex Holding Company Announces Positive Type C Meeting with the Fda and Reaches Agreement on Path Forward to File an Nda for Sp-102 in Lumbosacral Radicular Pain (Sciatica)

Scilex Holding Company Announces New Data From Deeper Skin Penetration Studies to Support SP-103 (lidocaine topical system) 5.4%, a Triple Strength Formulation of ZTlido®, in Treatment of Musculoskeletal Pain Disorders

Scilex Holding Company Announces Management Changes

Scilex Holding Company Announces Management Changes

Scilex Holding Company Announces the Completion of its SP-103 Phase 2

Scilex Holding Company Presents Oral and Poster Presentations on ZTlido (lidocaine Topical System) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV

Scilex Holding Company Provides Sales Guidance for the Month and Year to Date Ended August 31, 2023

Scilex Holding Company Announces Retirement of Jaisim Shah as Chief Executive Officer

Second quarter 2023 earnings released: US$0.19 loss per share (vs US$0.09 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.046 loss in 1Q 2022)

Scilex Holding Company's (NASDAQ:SCLX) 56% Dip In Price Shows Sentiment Is Matching Earnings

Scilex Holding Company Announces Complete Enrollment of A Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (Lidocaine Topical System) 5.4%, Triple Strength Formulation of Ztlido, for the Treatment of Acute Low Back Pain

Full year 2022 earnings released: US$0.17 loss per share (vs US$0.45 loss in FY 2021)

Scilex Holding Company Acquires Rights to FDA-Approved ELYXYB in the U.S. and Canada for the Acute Treatment of Migraine

Scilex Holding Company, Annual General Meeting, Apr 06, 2023

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin